Bionomics’ Victory – Analysts Note Optimism Around Promising Prospects for PTSD Treatment – Bionomics (NASDAQ:BNOX)
Earlier today, Bionomics Limited BNOX announced topline results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic stress disorder (PTSD). The trial met its primary endpoint of change in the Clinician-Administered PTSD…